Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
PDF

Case Report

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation

Turk J Anaesthesiol Reanim 2022;50(3):228-231 DOI: 10.5152/TJAR.2021.20450
, , , ,
PDF
Permissions

Abstract

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

Keywords: Antifibrotic, COVID-19, pirfenidone, pulmonary fibrosis, respiratory distress